Loading...
XSHG
600513
Market cap592mUSD
Jul 10, Last price  
15.49CNY
1D
10.01%
1Q
-31.37%
Jan 2017
15.33%
IPO
395.23%
Name

JIANGSU LIANHUAN PHARMACEUTICAL CO. LTD

Chart & Performance

D1W1MN
XSHG:600513 chart
P/E
P/S
1.63
EPS
Div Yield, %
0.63%
Shrs. gr., 5y
-0.05%
Rev. gr., 5y
14.37%
Revenues
2.71b
+25.52%
166,239,532194,783,184225,372,855259,893,808289,442,020324,214,970571,879,604623,302,812668,688,165642,432,916604,860,656689,099,3481,019,238,7321,290,332,6611,386,038,5801,645,816,3991,955,156,7812,174,100,3042,160,457,1592,711,858,051
Net income
-98m
L
7,826,10110,146,70213,144,74317,198,97420,334,21724,507,89433,989,07438,326,10043,995,34650,114,97562,690,17670,547,32573,556,82479,730,505103,001,884118,839,371141,370,533135,008,52284,159,991-98,332,446
CFO
-14m
L
10,144,0008,033,39117,442,00013,831,2708,426,00023,996,00016,941,00037,173,00069,500,00062,117,00070,285,0003,636,000-92,000,000-9,870,00091,936,547138,345,000127,590,000160,702,00010,766,000-14,464,534
Dividend
Jun 23, 20250.089 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Jiangsu Lianhuan Pharmaceutical Co., Ltd. operates within China, specializing in the production and distribution of chemical raw materials, pharmaceutical formulations, and organic intermediate compounds. Its extensive product range addresses diverse therapeutic needs, including cardiovascular issues, allergies, urinary tract conditions, infectious diseases, and immune system modulation. The enterprise was founded in 2000 and has its principal headquarters located in Yangzhou, China.
IPO date
Mar 19, 2003
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT